Austrian Biobanking Study for Sarcopenia
The investigators aim to set up a biobanking study in Graz, Austria, to study sarcopenia in liver cirrhosis and chronic inflammatory bowel disease by collecting a standardized dataset including routine clinical and biochemical tests; biosamples to assess novel biomarker as well as advanced clinical assessments. In a sm
| Condition(s) | Sarcopenia |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The investigators aim to set up a biobanking study in Graz, Austria, to study sarcopenia in liver cirrhosis and chronic inflammatory bowel disease by collecting a standardized dataset including routine clinical and biochemical tests; biosamples to assess novel biomarker as well as advanced clinical assessments. In a small country like Austria, a nationwide biobanking study can enhance research enormously. The investigators therefore aim to extend the registry to all tertiary liver care centers in Austria in a second step. |
| Who can participate | Inclusion Criteria: * Age \>18y * Informed consent * CT/MRI scan as part of routine care within +/-2 month of the study visit Exclusion Criteria: * Hepatic encephalopathy \> grade 2 and or other cognitive disorder not allowing informed consent * Hepatocellular carcinoma stage BCLC C or D * Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Medical University of Graz |
| Locations | Graz, Austria |
| Start date | 2023-02-01 |
| NCT ID | NCT06632743 |
| Official listing | https://clinicaltrials.gov/study/NCT06632743 |